Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Accelerated titration design].

H Minami1

  • 1National Cancer Center Hospital East.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 4, 2000
PubMed
Summary
This summary is machine-generated.

Accelerated titration designs in phase I cancer trials reduce patient numbers at low doses. Design 2 is recommended for Japanese phase I studies due to its efficiency and practicality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody': [ESMO Open volume 9 issue 6 (2024) 103476].

ESMO open·2024
Same author

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.

ESMO open·2024
Same author

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.

International journal of clinical oncology·2020
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Pharmacology

Context:

  • Phase I trials for anticancer agents aim to identify maximum tolerated doses.
  • Traditional designs often treat patients at sub-therapeutic doses.
  • Accelerated titration designs offer a potential solution to improve efficiency.

Purpose:

  • To evaluate the acceptability and performance of accelerated titration designs in phase I cancer trials.
  • To compare design 2 and design 4 based on patient numbers, dose escalation, and safety.
  • To recommend an optimal accelerated design for phase I studies in Japan.

Summary:

  • Simulations showed accelerated titration designs 2 and 4 reduced patients at low doses and undertreated patients.
  • Design 2 uses modified Fibonacci for dose steps and Design 4 uses 100% escalation.

Related Experiment Videos

  • Design 2 is recommended for Japan due to simpler decision-making compared to Design 4's reliance on three chemotherapy courses.

    • Impact:

    • Successfully reduces the number of patients treated at biologically inactive doses.
    • Minimizes undertreatment while avoiding overtreatment in early-phase oncology studies.
    • Provides a practical and efficient design (Design 2) for dose escalation in Japanese phase I clinical trials.